Mipasetamab uzoptirine  (Synonyms: ADCT-601)

Mipasetamab uzoptirine (ADCT-601) is an AXL-targeted antibody-drug conjugates (ADCs). Mipasetamab uzoptirine consists of a humanized anti-AXL antibody, a cleavable linker and the potent pyrrolobenzodiazepine (PBD) dimer cytotoxin SG3199. Mipasetamab uzoptirine can be used for the research of cancers^[1].

Mipasetamab uzoptirine binds to both soluble and membranous AXL, and is rapidly internalized by AXL-expressing tumor cells, allowing release of PBD dimer, DNA interstrand cross-linking, and subsequent cell killing^[1].
Mipasetamab uzoptirine selectively inhibits growth of AXL-positive human cancer cell lines (Panc-1, A-172, SK-LU-1, MDA-MB-231, SK-OV-3, NCI-H1299, and SN12C)^[1].
Mipasetamab uzoptirine (0 h, at 4°C) shows strong cell surface binding in SN12C cells, and colocalize well with lysosome at 1 h^[1].
Mipasetamab uzoptirine increases DNA interstrand cross-links levels in SN12C cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Mipasetamab uzoptirine (0.3-1 mg/kg, i.v.) inhibits tumor growth in MDA-MB-231 TNBC xenograft and SN12C xenograft mice model^[1].
Mipasetamab uzoptirine (6 mg/kg, i.v.) is well tolerated and shows excellent stability in rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2304799-73-1

[Mipasetamab uzoptirine]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Zammarchi F, et al. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers. Mol Cancer Ther. 2022 Apr 1;21(4):582-593.  [Content Brief]